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■ PURPOSE: To determine whether the 6-minute walk test (6MWT) is a  
predictor of peak oxygen uptake (V˙o2) in patients with idiopathic  
pulmonary arterial hypertension (IPAH).
■ METHODS: A total of 157 patients treated for IPAH completed a 6MWT in 
accordance with American Thoracic Society standards. Heart rate, 
pulse oximetry, and Borg rating of perceived exertion were determined 
at baseline and posttest. A cardiopulmonary exercise test (CPET) was 
performed on a cycle ergometer using a ramp protocol. Participants 
were stratified post hoc by age into 3 groups: children (n = 26), ado-
lescents (n = 49), and adults (n = 82). Multiple linear regression anal-
ysis was performed to predict peak V˙o2 from the 6MWT.
■ RESULTS: The regression equation generated for the children was the only 
model to strongly predict peak V˙o2 (r = 0.87; P < .001). Similar mod-
els for adolescent (r = 0.59; P < .001) and adult groups (r = 0.68; 
P < .001) did not achieve the same level of correlation.
■ CONCLUSION: Six-Minute Walk Test was able to accurately predict peak 
V˙o2 in children (6-12 years) with IPAH; however, the model was weak-
er for predicting peak V˙o2 in older populations. These findings suggest 
that 6MWT may be as valid a test for predicting peak V˙o2 in children 
with IPAH as CPET measured peak V˙o2. In older IPAH populations, 
CPET is the only reliable method for the evaluation of peak V˙o2.
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The cardiopulmonary response to exercise is an 
important clinical assessment tool, as it provides an 
integrated assessment of the respiratory, cardiac, and 
metabolic systems. The current gold standard method 
for assessing aerobic exercise response in humans is 
the maximum incremental cardiopulmonary exercise 
test (CPET). Peak V˙ o2, measured by a CPET, has been 
widely used to assess functional capacity and predict 
survival in patients with advanced symptomatic heart 
failure and respiratory dysfunction.1,2 However, CPET 
requires the use of expensive equipment and trained 
medical team supervision to conduct and evaluate 
each test.
Submaximal tests, like the 6-minute walk test 
(6MWT), provide useful information on daily physical 
performance that are safe, simple, standardized, and 
inexpensive. The 6MWT offers a better estimation of 
daily living activities than other walk tests3 and the 
American Thoracic Society has endorsed and published 
guidelines for performing the 6MWT in clinical settings.4
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The 6MWT is an independent predictor of morbid-
ity and mortality in adult patients with heart failure,1 
left ventricular dysfunction,5 chronic respiratory dis-
ease,6 cystic fibrosis, and pulmonary hypertension.2 In 
addition, the 6MWT is a significant predictor of sur-
vival in patients with pulmonary hypertension7-11 and 
is used in clinical trials for IPAH medications.12
In addition to other health limiting and debilitating 
conditions, patients with lung or heart disease may 
show a reduced 6-minute walk distance (6MWD).13-16 
Greater pre-transplantation 6MWD also correlates 
with shorter intensive care unit stays after pediatric 
lung transplantation.17
Correlation between V˙ o2 from CPET and 6MWT in 
healthy children18 and correlation between CPET and 
6MWT in patients with IPAH2 has been reported by 
others but not prediction of V˙ o2 peak from 6MWT. 
Ross et al19 attempted to predict peak V˙ o2 from 6MWD 
in patients with different cardiopulmonary disorders, 
suggesting poor prediction accuracy for assessing 
individuals for clinical purposes. In an obese nonadult 
group, body mass index (BMI) and 6MWD were sig-
nificant factors predicting peak V˙ o2, although no coef-
ficient of determination for the regression equation 
was cited.20 The 6MWT does not seem to predict peak 
V˙ o2 in adult patients with heart failure.
21 However, no 
other study has tried to predict peak V˙ o2 from 6MWT 
in children, adolescents, or adults with IPAH. Maximal 
exercise testing in IPAH populations involves a certain 
risk and requires supervision by well-trained and 
experienced health care professionals.
Thus, the aim of this study was to determine 
whether the 6MWT could accurately predict peak V˙ o2 
in patients with IPAH, which could provide health care 
professionals an easily implemented and inexpensive 
tool in the evaluation and followup of patients.
METHODS
The study was conducted in accordance with the 
amended Declaration of Helsinki. The Columbia 
University Medical Center institutional review board 
approved the study protocol and waived the need for 
patient consent due to the retrospective nature of the 
study.
Patients
One hundred fifty-seven patients being treated for 
IPAH from 2003 to 2013 were included in this study. 
Patients were diagnosed with IPAH by right-sided 
heart catheterization measurement of arterial pulmo-
nary pressures > 25 mmHg.22,23 Subjects were strati-
fied post hoc by age into 3 groups (children: 6-12 
years; adolescents: 13-18 years; and adults: ≥19 years) 
for between-group comparisons of anthropometric 
and 6MWT variables.
Assessments
Subjects were tested in the pediatric exercise labora-
tory as part of a standard of care for IPAH visits to the 
Pulmonary Hypertension Center of New York 
Presbyterian/Columbia University Medical Center. 
Each patient performed a pulmonary function test, 
CPET, and 6MWT, all on the same day. Height, 
weight, and age were gathered prior to the test. 
Patients were familiar with the tests.
Pulmonary Function Test
Forced vital capacity, slow vital capacity, and maxi-
mum voluntary ventilation were measured. Pulmonary 
function tests were performed on a Breeze Suite CPX 
Ultima (Medgraphics, St. Paul, MN).
Cardiopulmonary Exercise Test
The CPET was performed on a Lode Corival V2 (Lode 
BV, Groningen, the Netherlands) cycle ergometer fol-
lowing a ramp protocol with increments of 5, 10, 15, 
20, or 25 watts/min (depending on fitness level and/
or previous tests) until volitional fatigue. Three minutes 
of baseline data were collected followed by 3 minutes 
of unloaded warm-up cycling. The ramp protocol was 
started after the 3-minute warm-up. Once the patient 
reached his or her maximum values, a 3-minute cool-
down of unloaded cycling was performed as part of a 
10-minute recovery period, until return to baseline 
levels and/or until symptoms, if any, resolved.24 The 
following data were collected during the cycle ergom-
eter test: time, work in watts, real-time 12-lead elec-
trocardiogram including heart rate using a CardioPerfect 
WorkStation (Welch Allyn, Skaneateles Falls, NY), 
systolic and diastolic blood pressures by using the 
standard arm cuff technique (W. A. Baum Company, 
Inc, Copiague, NY), noninvasive peripheral oxygen 
saturation using a Datex-Ohmeda 3900P pulse oxime-
ter (Datex-Ohmeda, Madison, WI), O2 uptake and 
other gas exchange parameters through breath-by-
breath analysis of expired air via Breeze Suite CPX 
Ultima (Medgraphics).
6MWT
The 6MWT was performed in a 30-m hallway where 
the patients were instructed to walk as far as possible 
in 6 minutes by walking back and forth in a 30-m 
hallway at their own speed and pace following 
American Thoracic Society guidelines.4,25 Oxygen sat-
uration using a finger sensor and a 3900P pulse oxi-
meter (Datex-Ohmeda) and a rating of perceived 
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exertion (RPE) using the Borg CR10 scale26 were col-
lected at baseline and postwalk.
Statistical Analysis
The data were statistically analyzed using the PASW 
Statistics, version 18.0, for Windows (SPSS Inc, 
Chicago, IL). Continuous variables were presented as 
mean ± standard deviation. To evaluate whether 
anthropometric and 6MWT variables were different 
between the 3 groups, analysis of variance (ANOVA) 
was used. Finally, 3 multiple linear regression models, 
one for each group of participants, were determined. 
Variables such as weight, height, BMI, sex, walk 
speed, resting heart rate, and RPE were included in 
the analyses. A backward elimination approach was 
used to finalize the regression models. If the slope for 
an independent variable was not found to be statisti-
cally significantly different than zero at α = .05, that 
independent variable was excluded from the model. 
To assess the fit of the predictive model, we used 
conventional linear regression models according to 
the coefficient of determination (R2). A paired Student 
t test was used to compare the mean values for the 
measured and the estimated peak V˙ o2 measurements. 
Pearson correlation coefficient (r) was used to assess 
the linear bivariate relationship among estimated and 
measured peak V˙ o2. For all tests, a P value < .05 was 
considered statistically significant.
RESULTS
The baseline characteristics of the sample are shown 
in Table 1. Among the 26 children, mean age was 9.96 
± 1.66 years and 73% were female. In the group of 
adolescents (n = 49), mean age was 15.33 ± 1.80 
years and 47% were female. Among the 82 adults, 
mean age was 27.33 ± 6.70 years and 69.5% were 
female.
ANOVA revealed significant differences between 
age groups for height (F2,156= 66.384; P < .001), 
weight (F2,156= 24.453; P < .001), BMI (F2,156= 11.943; 
P < .001), and peak heart rate (F2,156= 6.8; P = .001). 
No significant differences were found between groups 
for resting heart rate (F2,156= 1.91; P = .152), 6MWD 
(F2,156= 0.195; P = .823), walking speed (F2,156= 
0.195; P = .823), and RPE (F2,156= 1.39; P = .252).
For the linear regression analysis, the 3 age 
groups were children, adolescents, and adults and 3 
independent multiple linear regressions were mod-
eled. The variables—sex (0 = female, 1 = male); 
weight; height; BMI; walk speed; resting heart rate; 
and RPE—were included in the models. Final mod-
els included variables that yielded the highest 
R2 values.
Table 2 shows the standardized and nonstandard-
ized coefficients for the linear regression model. 
Using standardized coefficients, in the first model 
(children), weight, BMI, and height (−4.72, 3.10, and 
1.44, respectively) contributed most to the model that 
predicted peak V˙ o2. The remaining variables (sex, 
walk speed, RPE, and resting heart rate) contributed 
less to the prediction. In the second model (adoles-
cents), the walk speed contributed most to the predic-
tion model while RPE and height contributed less. In 
the third model (adults), the variable that contributed 
the most was 6MWD (0.48), before sex (0.30), height 
and weight to estimate peak V˙ o2.
T a b l e  1  • Characteristics of Participants and 6MWT Data
Children (n = 26) Adolescents (n = 49) Adults (n = 82)
Age, y 9.96 ± 1.66 15.33 ± 1.80 27.33 ± 6.70
Height, cm 140.15 ± 12.88 160.98 ± 9.48a 164.67 ± 8.24a,b
Weight, kg 35.09 ± 13.31 52.42 ± 17.80a 62.85 ± 19.16a,b
BMI, kg/m2 17.37 ± 3.81 19.98 ± 5.47 23.02 ± 5.96a,b
Resting HR, bpm 90.19 ± 22.01 88.31 ± 15.95 83.84 ± 15.51
Peak HR, bpm 153.12 ± 26.22 152.04 ± 20.88 137.10 ± 28.58a,b
6MWD, m 471.15 ± 89.43 455.78 ± 84.63 459.77 ± 115.12
Walking speed, m/s 1.31 ± 0.25 1.27 ± 0.24 1.28 ± 0.32
Dyspnea, Borg scale 0-10 1.60 ± 2.11 0.99 ± 1.30 1.31 ± 1.44
Peak V˙  o2, mL/kg/min 22.07 ± 6.67 20.59 ± 6.23 16.03 ± 6.33
Abbreviations: BMI, body mass index; HR, heart rate; 6MWD, 6-minute walk distance; 6MWT, 6-minute walk test; V˙ o2, oxygen uptake.
aSignificantly different from children (P < .05).
bSignificantly different from adolescents (P < .05).
JCRP-D-14-00189.indd   3 16/02/16   5:27 PM
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
4 / Journal of Cardiopulmonary Rehabilitation and Prevention 2016;00:1-6 www.jcrpjournal.com
Assessment by the Student t test showed no sig-
nificant differences between the measured and the 
estimated peak V˙ o2 for children, adolescents, and 
adults. There were significant correlations between 
measured and estimated peak V˙ o2 in the 3 groups 
(children, r 2 = 0.873; adolescents, r 2 = 0.591; and 
adults, r 2 = 0.681, P < .001 for all). Figure 1  shows 
this correlation between measured peak V˙ o2 from the 
exercise test (peak V˙ o2-CPET) and estimated peak 
V˙ o2 from 6MWT (peak V˙ o2-6MWT) for all 3 groups 
(children, adolescents, and adults) expressed in 
mL/kg/min.
DISCUSSION
The primary result of this study was that a simple 
6MWT may be able to predict peak V˙ o2 in children 
with IPAH. However, the 6MWT was not able to pre-
dict peak V˙ o2 in other patients with IPAH. This is the 
first study that attempted to predict peak V˙ o2 from 
6MWT solely in patients with IPAH. Being able to 
predict peak V˙ o2 from 6MWT would give physicians 
and other health care professionals an easy, inexpen-
sive, and simple tool for the followup of the disease. 
The 6MWT was a strong predictor of peak V˙ o2 in 
children; however, the predictions were weaker in 
adolescents or adults.
Although peak V˙ o2 was predicted (r
2= 0.83) in the 
children's group, peak V˙ o2 alone does not provide 
enough information for the treatment and prognosis 
of patients with IPAH. Peak V˙ o2 is only 1 of the many 
variables obtained from a CPET. Peak V˙ o2 would only 
show a decrease in aerobic fitness in these patients 
but it would not determine what contributed to the 
decrease. In children, up to 12 years of age, the 
6MWT may be used to predict peak V˙ o2, although a 
previous CPET would always be highly recommended 
and the 6MWT could be used as a followup assess-
ment until adolescence.
Correlation between V˙ o2 from CPET and 6MWT in 
healthy children18 and correlation between CPET and 
6MWT in patients with IPAH2 have been reported by 
others, but no correlation between 6MWT predicted 
V˙ o2 and measured V˙ o2has been reported. However, 
Ross et al19 attempted to predict peak V˙ o2 from 6MWD 
in patients with different cardiopulmonary disorders 
and reported poor prediction accuracy for assessing 
individuals for clinical purposes. Body mass index and 
6MWD were the only significant factors to predict peak 
V˙ o2, in obese nonadult patients, although no coeffi-
cient of determination for the regression equation was 
reported.20 6MWT does not appear to accurately pre-
dict peak V˙ o2 in adult patients with heart failure.
21 
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Weight, BMI, and height have been cited as the 
most important variables affecting 6MWD.27,28 
Consistent with these findings, our models showed 
that these 3 variables have the strongest effect on the 
linear regression to predict peak V˙ o2 in children.
As expected, IPAH subjects showed lower 6MWD 
than healthy patients from other studies: children with 
IPAH averaged 471.15 ± 89.43 meters versus 664 ± 
65.3 meters29 and 619.2 ± 115.2 meters30 in healthy 
children; adolescents with IPAH walked 455.78 ± 
84.63 meters versus 699.2 ± 87 meters30 found in 
healthy adolescents; IPAH adults averaged a 6MWD of 
459.77 ± 115.12 meters versus the distances averaged 
by other healthy adults of 615.5 ± 44 meters31 and 672 
± 83 meters.32
Although a 6MWT may not be robust enough to 
predict peak V˙ o2 in adolescents and adults, it remains 
a very important tool to predict morbidity and mortal-
ity in a clinical setting. It is also important in predict-
ing shorter intensive care unit stays after pediatric 
lung transplantation,17 as well as predicting morbidity 
and mortality in adult patients with left ventricular 
dysfunction.5 The 6MWT is a significant predictor of 
survival in patients with IPAH.7-11 It is still used in 
clinical trials for IPAH medication use.12
Although performing a simpler submaximal test, 
like the 6MWT, with children with IPAH may predict 
peak V˙ o2, it would not give health care professionals 
the necessary information to evaluate functional 
capacity. The 6MWT is not able to predict peak V˙ o2 in 
most patients with pulmonary hypertension, but it is 
an important tool for the evaluation and followup of 
patients with IPAH.
The small sample size, specifically in the children's 
group (n = 26, with only 7 males), is a limitation of 
this study. In future research, a larger sample size, 
especially in the children's group, is needed. The 
small sample size in this study prevented us from 
validating the regression equations. Also, future stud-
ies comparing each group with a control group could 
shed more light on how and what prediction equa-
tions used in the study would apply to a normal or 
healthy population.
CONCLUSION
The measured peak V˙ o2 of the patients varied greatly 
by age. A linear regression equation developed from 
the 6MWT was able to accurately predict peak V˙ o2 in 
children (6-12 years) with IPAH; however, the model 
failed to predict peak V˙ o2 in older populations. These 
findings suggest that peak V˙ o2 measured by CPET is 
still the gold standard for assessing aerobic exercise 
capacity in patients with IPAH. However, the 6MWT 
However, no other study has tried to predict peak V˙ o2 
from 6MWT in children, adolescents, or adults with 
IPAH.
Figure 1. Measured (CPET) versus predicted (6MWT) values for 
peak  V
.
  o2 in (A) children, (B) adolescents, and (C) adults. CPET 
indicates cardiopulmonary exercise test; V
.
  o2, oxygen uptake; 6MWT, 
6-minute walk test.
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could still be a valuable test for prognostic purposes 
when performing a CPET is not an option. It could 
also be of great value as a complement to the CPET. 
Future research should be conducted to validate the 
regression equations.
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